Preamble
This is volume 16 in the series Modern Problems of Pharmacopsychiatry. It was developed on the basis of presentations made in the course of the Symposium on Multicentre Trials held in the framework of the CINP-12 Congress in Göteborg in 1980. The series editors are TA Ban (Tennessee Neuropsychiatric Institute, Nashville, Tennessee, USA); FA Freyhan (Washington, DC, USA); P Pichot (Paris, France), and W Pöldinger (Wil/St Gallen).

Aims
The material in this volume has been developed on the basis of presentations made in the course of the Symposium on Multicentre Trials held in the framework of the CINP-12 Congress in Göteborg in 1980. The discussions which followed the presentation of these papers, as well as further contacts with scientists who did not attend the symposium, convinced us that it may be of interest to publish this material, amended as necessary to include comments and ideas contributed during the discussions in the symposium. Papers in this volume deal with three themes: the first four describe general and methodological considerations in multicentre trials; the papers by Leeds, Gastpar, Linden and Schüssler present accounts of practical considerations - such as that of communication and collaboration with general practitioners and with scientists; finally, the last three describe examples of collaborative multicentre studies. We hope that the experience presented in this volume will be helpful to those undertaking collaborative work and interesting and informative to those who do not (Preface, page xi)

This volume is the first publication offering practical guidance in the organization, management, and interpretation of multicentre and collaborative trials designed to elicit data in clinical psychopharmacology (Publisher’s statement, back cover).

Contents (xi+114 pages)
[Sub-headings omitted]
Contributors
Preface
Aims and implementation of multicentre studies (N Sartorius, H Helmchen)
  Reasons for undertaking multicentre studies
  Variables in multicentre studies
  Levels of interdependence among centres: coordinated, cooperative and collaborative studies
  Standards
  Reference
Multicentre clinical trials: methodological aspects (TA Ban, WH Wilson)
  Introduction
  Experimental design
  Experimental population
  Treatment specifications
  Assessment procedures
  Data analysis
  Conclusions
  References
Cultural factors in the organisation of multicentre trials (BB Sethi, R Prakash)
  Diagnostic practice and nosological system
  Cultural variations in response to evaluational tools
  Influence of attitude on drug effects
  Culture, nutrition, human biology and pharmacokinetics
  Cultural influence on drug side effects
  Concluding remarks
  References

Methodological and practical aspects of a multicentre study of reliability of psychopathological assessment (H Busch, M v. Cranach, W Gulbinat, E Renfördt, J Tegeler)
  Design of the study
  Measures of reliability
  Results
  Concluding remarks
  References

The role of communication in multicentre trials (AA Leeds)

Collaborative studies with psychiatric practitioners (M Linden, G Schüssler)
  The need for research in psychiatric practice
  Differences between patients in general practice, in psychiatric practice and in psychiatric hospitals
  Consequences for research resulting from population differences
  Characteristics of private practice settings
  Research initiatives in the private practice field
  Organization and functioning of a collaborative study group between private practitioners and a research institute
  Summary
  References

Experience of organizing collaboration of general practitioners in psychiatric studies in a specific catchment area (M Gastpar)
  Introduction
  Studies
  Experiences and problems
  References

WHO-coordinated collaborative studies on the effects of psychopharmacological drugs in different populations (N Sartorius)
  Studies of dose effects of antidepressant medication in different populations
  Studies of dose effects of antipsychotic medication in different populations
  Studies of effects of benzodiazepines and therapeutic counselling in different populations
  Conclusions
  References

Comments on multicentre trials of antidepressant drugs (H Hippius, N Matussek)
  Size of samples
  Case selection and classification
  Psychopathological rating
  Estimation of plasma levels
  General importance of multicenter trials
  Summary
  References
Drug monitoring in psychiatry (B Müller-Oerlinghausen, L Schmidt, E Rüther)
Definition and aims of drug monitoring
A national project on drug monitoring in psychiatry
Features of drug monitoring in psychiatry
Methodology
Strategy of collaboration in drug monitoring
References
Subject index

Authors
The volume editors are N Sartorius (Division of Mental Health, World Health Organization, Geneva, Switzerland) and H Helmchen (Psychiatrische Klinik und Poliklinik der Freien Universität Berlin, Berlin, Federal Republic of Germany). The contributors are TA Ban (Tennessee Neuropsychiatric Institute, Nashville, Tennessee, USA); H Busch (Psychiatrische Klinik und Poliklinik der Freien Universität Berlin, Berlin, Federal Republic of Germany); M v Cranach (Nervenkrankenhaus, Kaufbeuren, Federal Republic of Germany); M Gastpar (Psychiatrische Universitätsklinik Basel, Basel, Switzerland); W Gulbinat (Division of Mental Health, World Health Organization, Geneva, Switzerland); H Hippius (Psychiatrische Klinik und Poliklinik der Universität München, München, Federal Republic of Germany); AA Leeds (Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, National Institute of Mental Health, Rockville, MD, USA); M Linden (Psychiatrische Klinik und Poliklinik der Freien Universität Berlin, Berlin, Federal Republic of Germany); N Matussek (Psychiatrische Klinik and Poliklinik der Universität München, München, Federal Republic of Germany); B Müller-Oerlinghausen (Psychiatrische Klinik und Poliklinik der Freien Universität Berlin, Berlin, Federal Republic of Germany); R Prakash (Department of Psychiatry, King George’s Medical College, Lucknow, India); E Renfordt (Psychiatrische Klinik und Poliklinik der Freien Universität Berlin, Berlin, Federal Republic of Germany); E Rüther (Psychiatrische Klinik und Poliklinik der Universität München, München, Federal Republic of Germany); L Schmidt (Psychiatrische Klinik und Poliklinik der Freien Universität Berlin, Berlin, Federal Republic of Germany); G Schüssler (Psychiatrische Klinik und Poliklinik der Freien Universität Berlin, Berlin, Federal Republic of Germany); BB Sethi (Department of Psychiatry, King George’s Medical College, Lucknow, India); J Tegeter (Psychiatrische Klinik der Universität Düsseldorf, Düsseldorf, Federal Republic of Germany); and, WH Wilson (Tennessee Neuropsychiatric Institute, Nashville, Tennessee, USA).